PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE YEAR 2026 ENDED MARCH 31, 2026
Rhea-AI Summary
PetVivo Holdings (OTCQX: PETV) will report financial results for the year ended March 31, 2026, on Monday, June 29, 2026, after market close. A conference call and live webcast are scheduled for 5:00 p.m. CT (6:00 p.m. ET) the same day.
Positive
- None.
Negative
- None.
News Market Reaction – PETV
In the Jun 26 session, PETV gained 6.25%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 08 | Investor event update | Positive | +9.4% | Announcement of virtual investor event focused on product feedback and access expansion. |
| Apr 29 | AI partnership news | Positive | -2.3% | Disclosure of Tier 1 AI contract to deploy investor-intelligence tools for PETV. |
| Apr 21 | Investor conference presentation | Positive | -2.4% | Upcoming Market Movers Summit presentation highlighting Spryng and PrecisePRP products. |
| Feb 17 | Earnings results release | Positive | +4.0% | Fiscal Q3 and nine‑month 2026 results with commercial and R&D milestones highlighted. |
| Feb 10 | Earnings call scheduling | Neutral | +0.0% | Correction and rescheduling notice for fiscal Q3 2026 conference call timing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
PETV has generally reacted positively to operational updates and investor-focused events, with only one recent divergence on an AI-related partnership announcement.
Key Terms
otcqx financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, MN, US, June 25, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV) (OTCID: PETVW), in cooperation with its wholly-owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, will report financial results for the year ending March 31, 2026, on Monday, June 29, 2026 after market close. The company will host a conference call to discuss these results at 5:00 p.m. CT (6:00 p.m. ET) on the same day.
Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo’s Investor Relations website at:
https://audience.mysequire.com/webinar-view?webinar_id=da774c66-358e-4c59-ab77-3d2a687cf6fb
A replay of the webcast will be available through the same link following the conference call. Participants can also access the call using the dial-in details below.
Date: Monday, June 29, 2026
Time: 5:00 p.m. CT (6:00 p.m. ET)
Dial-in: +1 719 359 4580
Meeting ID: 82601091950
Passcode: 101283
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly owned subsidiaries Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI Inc., is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protect the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG® with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP®, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
For more information about PetVivo Holdings, Inc. or its innovative products, Spryng and PrecisePRP, please contact info1@petvivo.com or visit petvivo.com, petvivoanimalhealth.com and sprynghealth.com.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
